Bactericidal activity of the alternative complement pathway generated from 11 isolated plasma proteins.
about
Killing of Microbes and Cancer by the Immune System with Three Mammalian Pore-Forming Killer ProteinsMolecular organization of C9 within the membrane attack complex of complement. Induction of circular C9 polymerization by the C5b-8 assemblyBactericidal and bacteriolytic activity of serum against gram-negative bacteria.Sequential metabolic expressions of the lethal process in human serum-treated Escherichia coli: role of lysozyme.Disassembly of viral membranes by complement independent of channel formationAn evaluation of the role of properdin in alternative pathway activation on Neisseria meningitidis and Neisseria gonorrhoeae.Anti-mouse properdin TSR 5/6 monoclonal antibodies block complement alternative pathway-dependent pathogenesis.Killing of human melanoma cells by the membrane attack complex of human complement as a function of its molecular composition.Pseudomonas aeruginosa Psl polysaccharide reduces neutrophil phagocytosis and the oxidative response by limiting complement-mediated opsonization.Heptose I glycan substitutions on Neisseria gonorrhoeae lipooligosaccharide influence C4b-binding protein binding and serum resistancePerforin-2/Mpeg1 and other pore-forming proteins throughout evolutionPerforin-2 is essential for intracellular defense of parenchymal cells and phagocytes against pathogenic bacteria.Staphylococcal protein Ecb impairs complement receptor-1 mediated recognition of opsonized bacteria.Surface-associated heparin inhibits zymosan-induced activation of the human alternative complement pathway by augmenting the regulatory action of the control proteins on particle-bound C3bStudies on the mechanism of bacterial resistance to complement-mediated killing. II. C8 and C9 release C5b67 from the surface of Salmonella minnesota S218 because the terminal complex does not insert into the bacterial outer membrane.Studies on the mechanism of bacterial resistance to complement-mediated killing. I. Terminal complement components are deposited and released from Salmonella minnesota S218 without causing bacterial death.Localization of the membrane attack complex (MAC) in experimental immune complex glomerulonephritis.Opsonization of bacteroides by the alternative complement pathway reconstructed from isolated plasma proteins.Antibody-independent activation of the alternative complement pathway by measles virus-infected cellsDifferential complement resistance mediates virulence of Haemophilus influenzae type bPerforin-2 Protects Host Cells and Mice by Restricting the Vacuole to Cytosol Transitioning of a Bacterial Pathogen.Characterization of the susceptibility of Pseudomonas aeruginosa to complement-mediated killing: role of antibodies to the rough lipopolysaccharide on serum-sensitive strains.Interaction of complement with serum-sensitive and serum-resistant strains of Pseudomonas aeruginosa.Sensitivity of Capnocytophaga species to bactericidal properties of human serum.Serum sensitivity of a Pseudomonas aeruginosa mucoid strain.Multimeric complement component C9 is necessary for killing of Escherichia coli J5 by terminal attack complex C5b-9.Killing machines: three pore-forming proteins of the immune system.A study of inactivation of Chlamydia trachomatis by normal human serum.Inhibition of intracellular bacterial replication in fibroblasts is dependent on the perforin-like protein (perforin-2) encoded by macrophage-expressed gene 1.Hereditary properdin deficiency in three families of Tunisian Jews.Activation of the alternative and classical complement pathways by Entamoeba histolytica.Degree of antibody-independent activation of the classical complement pathway by K1 Escherichia coli differs with O antigen type and correlates with virulence of meningitis in newborns.Membrane changes induced by exposure of Escherichia coli to human serum.Stimulation of complement production in mice by N alpha-(N-acetylmuramyl-L-alanyl-D-isoglutamine)-N epsilon-stearoyl-L-lysine.Properdin Levels in Individuals with Chemotherapy-Induced Neutropenia.Inhibition of zymosan-induced alternative complement pathway activation by concanavalin A.Killing of an encapsulated strain of Escherichia coli by human serum.Serum bacterial reaction by the alternative pathway of complement: potentiation by target multiplicity and modulation by serum factors.Defective bactericidal reaction by the alternative pathway of complement in atopic patients.Rapid killing of Capnocytophaga canimorsus and Capnocytophaga cynodegmi by human whole blood and serum is mediated via the complement system.
P2860
Q28066477-1D46D67E-9A60-4FA7-A7B6-37D3D0FA811AQ28610976-69B1697B-E2F5-4C46-B218-388ECEDC6B43Q33627395-45BAC45E-5077-4786-9FA0-C548651FB4BDQ33903750-EEC7946D-D048-4EDB-822B-6AD7C8EA9670Q33981914-C2A1DC86-43D1-4F7A-A5E7-7172E1E93FF0Q34105747-CB822AED-7981-465F-A5F3-816AA89F4096Q35149952-E1942D35-EEEA-4440-B812-ED80856F06A6Q35576037-C94A5F6C-64A2-4D4D-9136-33088D8C992DQ35738790-38E0A19F-72CE-4916-BC34-88B1176E936FQ35949845-DC4CCBF1-E01A-4845-A3F4-67B68234F4ACQ36143393-78774E69-340A-4950-9FFE-64F56801D89CQ36227119-CB357975-FEF6-4354-AB12-C3F23D1E5321Q36300934-197BC8F9-B640-4F8B-9ACE-91502F0BE021Q36343010-A2CFA643-974D-47EA-ABB2-6D4755D9A709Q36346256-8174FB76-9F9E-4557-BF1C-464C09F00B20Q36346273-9D097BA1-91B5-44FB-AEF5-BBB18DA38F5AQ36347889-5A6901DD-7BAE-403B-930F-E27FED175550Q36352460-9578F9C6-B9E2-4E2E-9E92-DC9C69847026Q36353461-D9C29607-292D-4C31-8E68-824876F46421Q36433753-2C237D03-EB69-4D0B-8511-89053AADE78CQ36728051-97444EB1-817C-458E-B92E-735DF7972C5CQ36994774-7AB1D8DD-EE0C-4C67-AFDD-C82011328DABQ37013891-C8DB7E6F-D8B7-43C5-851A-88DD6ABD2A30Q37052911-5C1B53B3-4966-405A-950B-B4208D5EF858Q37079212-9CB2DAAE-6495-4AAF-9349-56EB2F734655Q37541540-D8548245-0889-4819-A9D3-ECF1046A01BEQ37693343-12182748-E809-406A-B591-F16C71BF0EC2Q37906481-42E92D49-DD4F-400E-81D1-4775425AF888Q39222791-2928F4D6-69E0-4BF4-9E56-CDE1F5E9CFCFQ39436689-8725E402-148C-4D3A-BA1C-C473132C31EBQ40170493-DD4AB240-BCB9-4B7D-B3A6-A5247D8BA595Q40181929-7012A6FB-CB56-4818-A783-648F192AD07CQ40182160-3B1A343A-9AA2-498F-AFF4-FB44C65D23F0Q40182443-F9EB71AB-9050-413F-9ED9-6D5525DEE4EEQ40222861-2F6B18F8-3124-4A26-9DE0-2B6E85611BFAQ40599517-D66B628C-46FC-43BF-959E-78FE93023166Q40599630-55A7FAEA-A2B5-479F-8DF9-BD738DF432C2Q40611666-D10D71AC-67A1-4EA9-AB3D-42C079D41131Q40611674-559F3CF9-AB47-41CE-9862-CF44618FEA49Q40982422-F435DDCA-A1A1-4ABC-84AD-B0B3217CE4A0
P2860
Bactericidal activity of the alternative complement pathway generated from 11 isolated plasma proteins.
description
1979 nî lūn-bûn
@nan
1979年の論文
@ja
1979年学术文章
@wuu
1979年学术文章
@zh-cn
1979年学术文章
@zh-hans
1979年学术文章
@zh-my
1979年学术文章
@zh-sg
1979年學術文章
@yue
1979年學術文章
@zh
1979年學術文章
@zh-hant
name
Bactericidal activity of the a ...... m 11 isolated plasma proteins.
@ast
Bactericidal activity of the a ...... m 11 isolated plasma proteins.
@en
type
label
Bactericidal activity of the a ...... m 11 isolated plasma proteins.
@ast
Bactericidal activity of the a ...... m 11 isolated plasma proteins.
@en
prefLabel
Bactericidal activity of the a ...... m 11 isolated plasma proteins.
@ast
Bactericidal activity of the a ...... m 11 isolated plasma proteins.
@en
P2093
P2860
P356
P1476
Bactericidal activity of the a ...... m 11 isolated plasma proteins.
@en
P2093
Morrison DC
Müller-Eberhard HJ
Schreiber RD
P2860
P304
P356
10.1084/JEM.149.4.870
P407
P577
1979-04-01T00:00:00Z